Top Markets
#1 Purr Purr +62.52%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +26.23%
#4 Kinetiq Kinetiq +23.23%
#5 ApeX ApeX +22.46%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +20.08%
#7 Zora Zora +19.59%
#8 OriginTrail OriginTrail +17.77%
#9 Non-Playable Coin Non-Playable Coin +17.52%
#10 Morpho Morpho +16.59%
Coin of the day
Purr Purr
Settings
Language
ENGLISH
Currency
USD
Theme
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX
Rank in Stocks #21215
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical... Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Share Price
$7.51
Last synced: 2026-08-21
Market Cap
$112.52M
Change (1 day)
0.13%
Change (1 year)
128.27%
Country
US
Trade Cumberland Pharmaceuticals Inc. (CPIX)

Category

Healthcare
Operating Margin for Cumberland Pharmaceuticals Inc. (CPIX)
Operating Margin as of 2026 TTM: 0.00%
According to Cumberland Pharmaceuticals Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Cumberland Pharmaceuticals Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.